



**Descriptive report of Adverse event following  
immunization (AEFIs)  
data in Saudi Arabia, Q1 2024**

DATA CAPTURE SECTION  
NATIONAL PHARMACOVIGILANCE CENTER



## General notes:

### Data Report: National Pharmacovigilance Centre


- **Source:** Spontaneous Vigilance System, National Pharmacovigilance Centre
- **Scope:** Adverse event following immunization reports. These are medical occurrences noted after the use of a vaccine but do not necessarily imply a direct causal link to the vaccine.
- **Parameters:**
  - Routine and Covid vaccine reports (Drug reports excluded)
  - Data extract from 1 Jan to 31 March, 2024

### Understanding Pharmacovigilance


The National Pharmacovigilance Centre plays a crucial role in post-market vaccine safety monitoring. By collecting and analyzing adverse event reports following immunization, it helps identify serious issues and facilitates interventions to protect public health.

### Important Notes


important to understand that reports of adverse events following immunization do not automatically prove that the vaccine caused the event. Careful assessment is necessary to establish any potential relationship.




### NUMBER of REPORTS BASED ON ORGANIZATION TYPE




### number of reports based on report type




### Gender




### Report seriousness




### number of reports by Serious AEFI




### number of reports by outcomes







The top 5 Vaccines by (trade name) reported in Q1 2024.



The top 5 AEFIs reported in Q1 2024.



AEFIs reports in 2024 vs 2023



Reports count based on regions for year 2024, quarter 1.



## Recommendation:

After Reviewing the reporting and statistics in 2023 and the first quarter of 2024. The recommendation suggests repeating in-person visits for all the regions in KSA to continue achieving the goal in the reporting process. The purpose of these visits would be to share best practices, address any remaining challenges, and celebrate successes.

## Action plan for the quarters in 2024:

- improving the reporting rate for vaccines during the year 2024.
- **in-person visits to all regions:** Conducting visits to all regions to increase awareness about reporting and explain the reporting mechanism through vigilance system.
- **Reviewing the barriers:** Identifying and assessing the problems and challenges that prevent effective reporting through the vigilance system.
- **Follow-up reporting:** After the physical visits, will implementing a system for continuous monitoring and follow-up of reporting efforts during the 2nd, 3rd, and 4th quarters of 2024.
- **Virtual meetings:** Convening meetings for each region after the quarter to review the extent of improvement in reporting rates.



